Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL23355919 | 0.97 | ALDH1A1 (0.42) | ALDH1A1POLBNPSR1L3MBTL1GAA | |
| Water SCHEMBL9364486 | 0.97 | ALDH1A1 (0.42) | ALDH1A1POLBNPSR1L3MBTL1GAA | |
| SCHEMBL12808404 | 0.91 | POLB (0.37) | ALDH1A1POLBNPSR1L3MBTL1MEN1 | |
| SCHEMBL14424483 | 0.88 | CA1 (0.42) | ALDH1A1POLBNPSR1GAACA1 | |
| SCHEMBL13943186 | 0.84 | CA12 (0.48) | ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL647080 | 0.81 | ALDH1A1 (0.44) | ALDH1A1POLBNPSR1L3MBTL1GAA | |
| SCHEMBL14435108 | 0.75 | KDM4E (0.39) | ALDH1A1POLB | |
| SCHEMBL13993792 | 0.74 | KDM4E (0.49) | ALDH1A1POLB | |
| SCHEMBL560454 | 0.64 | ALDH1A1 (0.59) | ALDH1A1CA1CA2CA9 | |
| SCHEMBL21625543 | 0.63 | CA1 (0.42) | ALDH1A1POLBNPSR1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310336-B1 | OPHTHALMOLOGICAL COMPOSITION COMPRISING ACECLIDINE AND MANNITOL FOR USE IN THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260069533-A1 | METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12533347-B2 | Compositions and methods for storage stable ophthalmic drugs | LENZ THERAPEUTICS OPERATIONS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4563162-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Lenz Therapeutics Operations, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250171729-A1 | BIOFERTILIZER COMPOSITIONS AND METHODS | KULA BIO INC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4552651-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Lenz Therapeutics Operations, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-3542798-B1 | ACECLIDINE FOR USE IN THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4482309-A2 | BIOFERTILIZER COMPOSITIONS AND METHODS | Kula Bio, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-12180206-B2 | Aceclidine derivatives, compositions thereof and methods of use thereof | LENZ THERAPEUTICS OPERATIONS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-12128036-B2 | Compositions and methods for storage stable ophthalmic drugs | LENZ THERAPEUTICS OPERATIONS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20040062746-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| EP-0625208-B1 | BIOCHEMICAL PURIFICATION OF SIMVASTATIN | MERCK & CO INC (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0354954-B1 | REAGENT AND METHOD FOR DETECTING RHEUMATOID FACTOR | BECKMAN INSTRUMENTS INC (US) | 1993-12-22 | — | — | EP | disclosed |
| WO-1993016188-A1 | BIOCHEMICAL PURIFICATION OF SIMVASTATIN | MERCK & CO., INC. (US) | 1993-08-19 | — | — | WO | disclosed |
| US-5223415-A | Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid) | MERCK & CO., INC. (US) | 1993-06-29 | — | — | US | disclosed |
| US-4914041-A | CONTAINING HEPARIN | BECKMAN INSTRUMENTS, INC. (US) | 1990-04-03 | — | — | US | disclosed |
| EP-0354954-A1 | REAGENT AND METHOD FOR DETECTING RHEUMATOID FACTOR. | BECKMAN INSTRUMENTS INC (US) | 1990-02-21 | — | — | EP | disclosed |
| WO-1989007765-A1 | NOVEL BUFFER AND METHOD FOR DETECTING RHEUMATOID FACTOR | BECKMAN INSTRUMENTS, INC. (US) | 1989-08-24 | — | — | WO | disclosed |
| EP-0158684-A1 | Hemoglobin-based blood gas control | Fisher Scientific Company (US) | 1985-10-23 | — | — | EP | disclosed |
| US-4485174-A | WITH BUFFER AND NUCLEOTIDE REDUCING AGENT | INSTRUMENTATION LABORATORY INC. (US) | 1984-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069533-A1 | METHODS FOR THE TREATMENT OF PRESBYOPIA | CHRM2, ADRB2, CHRM3 | ALDH1A1 3244/4885POLB 2257/4885NPSR1 3532/4885 |
| US-12180206-B2 | Aceclidine derivatives, compositions thereof and methods of use thereof | ACE, ACHE, ACE2 | ALDH1A1 469/4885POLB 989/4885NPSR1 4183/4885 |
| US-20040062746-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | CD14, HLA-C, HLA-A | ALDH1A1 3287/4885POLB 2883/4885NPSR1 2485/4885 |
| US-12533347-B2 | Compositions and methods for storage stable ophthalmic drugs | PDE6C, PDE6A, PDE6B | ALDH1A1 870/4885POLB 1134/4885NPSR1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.